Physiomics uses Virtual Tumour and other industry standard technologies to predict the effects of cancer treatment regimes for the biopharma industry.

How can we help you?

Solve cancer drug development challenges

Optimise combination regimens, manage drug resistance, scale up from mouse to human, predict immune-oncology effects

Learn more

See our range of cancer modelling experience

Find out more about drug targets, drug types and cell lines where we have significant experience

Learn more

Learn about Virtual Tumour

Flexible in-silico cell-cycle based model combining PK and PD effects to predict cancer growth inhibition.

Learn more

Any other questions?

If you don’t see what you need here, please contact us by clicking on the link below.

Contact Us

News & publications

Editorial Appointment

Physiomics plc (AIM: PYC), is pleased to announce that one of its long-term consultants and collaborators, Dr Hitesh Mistry, has been appointed to the…

Physiomics in the news: “Virtual tumour software: Physiomics starting to catch cancer world’s attention”

Physiomics’ cutting edge technology is starting to catch the attention of the world of oncology according to this article in the Daily Mail… Click…

Renewal of Agreement with Merck

Physiomics plc (Oxford, UK) is pleased to announce that, following a successful collaboration this year and pursuant to the Master Services Agreement signed with Merck,…

Results of AGM

The Company held its Annual General Meeting at its offices in Oxford on 20th November 2018 and is pleased to announce that all resolutions put to…